Monaco Asset Management SAM bought a new stake in Teladoc Health, Inc. (NYSE:TDOC – Free Report) in the second quarter, Holdings Channel reports. The institutional investor bought 3,167,979 shares of the health services provider’s stock, valued at approximately $26,864,000. Teladoc Health makes up about 2.1% of Monaco Asset Management SAM’s portfolio, making the stock its 2nd biggest holding.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in TDOC. IFP Advisors Inc increased its position in Teladoc Health by 412.1% in the 3rd quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after acquiring an additional 3,210 shares during the period. PNC Financial Services Group Inc. lifted its position in Teladoc Health by 177.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock worth $31,000 after acquiring an additional 2,810 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of Teladoc Health by 694.5% during the first quarter. EverSource Wealth Advisors LLC now owns 5,657 shares of the health services provider’s stock worth $31,000 after purchasing an additional 4,945 shares during the period. International Assets Investment Management LLC acquired a new stake in shares of Teladoc Health in the 4th quarter worth $45,000. Finally, Versant Capital Management Inc boosted its holdings in Teladoc Health by 33.3% in the 2nd quarter. Versant Capital Management Inc now owns 8,207 shares of the health services provider’s stock valued at $70,000 after purchasing an additional 2,052 shares in the last quarter. Hedge funds and other institutional investors own 76.82% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research firms recently commented on TDOC. Bank of America boosted their price objective on shares of Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Weiss Ratings upgraded Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Citigroup dropped their price objective on Teladoc Health from $11.00 to $7.50 and set a “neutral” rating for the company in a research note on Monday, August 3rd. Finally, Canaccord Genuity Group reduced their price objective on Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Five analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Teladoc Health currently has a consensus rating of “Hold” and a consensus target price of $7.54.
Insider Buying and Selling
In other Teladoc Health news, CEO Charles Divita III sold 19,132 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $145,977.16. Following the completion of the transaction, the chief executive officer owned 389,894 shares of the company’s stock, valued at approximately $2,974,891.22. This trade represents a 4.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Adam C. Vandervoort sold 7,906 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $60,322.78. Following the completion of the transaction, the insider directly owned 110,261 shares of the company’s stock, valued at approximately $841,291.43. This trade represents a 6.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 39,195 shares of company stock valued at $299,058. 0.70% of the stock is currently owned by company insiders.
Teladoc Health Trading Up 0.2%
NYSE:TDOC opened at $6.82 on Monday. The firm has a 50-day moving average price of $8.15 and a two-hundred day moving average price of $6.57. Teladoc Health, Inc. has a twelve month low of $4.40 and a twelve month high of $9.89. The company has a market capitalization of $1.24 billion, a P/E ratio of -6.89 and a beta of 2.12.
Teladoc Health (NYSE:TDOC – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.04. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The company had revenue of $606.93 million for the quarter, compared to the consensus estimate of $615.44 million. During the same quarter in the prior year, the firm earned ($0.19) earnings per share. The company’s revenue for the quarter was down 4.0% compared to the same quarter last year. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. On average, equities research analysts predict that Teladoc Health, Inc. will post -0.89 earnings per share for the current year.
About Teladoc Health
Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.
Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.
Read More
- Five stocks we like better than Teladoc Health
- The Metals Company’s Big Bet Now Comes Down to a License
- OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
- Meta and Tesla Are Rebounding From Oversold Levels—Now What?
- AMG’s Alternatives Boom Powers Record Growth
Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health, Inc. (NYSE:TDOC – Free Report).
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.
